Ionis Pharmaceuticals Q1 2025 Earnings Preview
New Harris Poll Findings Reveal HAE Patients Are Unsatisfied With Current Prophylactic Treatment Options, With Over 90% Interested in Trying New Therapies
Earnings Preview: IONS to Report Financial Results on April 30
Press Release: Ionis to Hold First Quarter 2025 Financial Results Webcast
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $54 From $55
H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $45
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Trending Stocks Today | ICAD Inc Soars 74.61% Post-Market
TD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating
Promising Potential of Ionis Pharmaceuticals' Olezarsen in SHTG Market With Competitive Pricing and Strong Market Potential
Ionis Pharmaceuticals: Promising Market Growth With Tryngolza Approval and Advancing Clinical Trials
Express News | Ionis Pharmaceuticals Inc : Citigroup Removes Stock From Its North American Focus List
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $52
Morgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
Express News | Ionis Pharmaceuticals Inc : Morgan Stanley Cuts Target Price to $52.00 From $55.00
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $60
Express News | Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday